ModifiedmhnPolicy CP.CPA.357

Clinical Policy: Icosapent Ethyl (Vascepa)

Covers medical necessity and prior authorization criteria for icosapent ethyl (Vascepa) for reduction of cardiovascular risk and treatment of hypertriglyceridemia for commercial line of business.

Policy Summary

Payermhn

PolicyClinical Policy: Icosapent Ethyl (Vascepa)

Policy CodePolicy CP.CPA.357

Change TypeRevised approval duration and statin trial criteria

Effective Date03.01.23

Next Review Date

Key ActionSubmit prior authorization with diagnosis, labs (fasting TG and LDL‑C) within 90 days and documentation of prior statin therapy or statin intolerance per criteria.

SourceLink

POLICY UPDATE CHANGES

Extended initial approval duration from 6 months to 12 months for maintenance medication for chronic condition; reduced statin adherence duration from 4 months to 8 weeks and simplified statin trial/failure criteria for moderate- and low-intensity regimens.

12 monthsapproval duration

≥500TG threshold (hyperTG)

150–499TG range (CVD)

41–100LDL‑C requirement

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

8 weeksstatin adherence

Coverage and Medical Necessity Criteria

Initial Therapy - Hypertriglyceridemia without ASCVD

Covered when ALL of the following are met

Hypertriglyceridemia without ASCVD initial: 1. Diagnosis of hypertriglyceridemia; 2. Age ≥ 18 years; 3. Fasting TG ≥ 500 mg/dL (laboratory result dated within 90 days); 4. Failure of a ≥ 3 consecutive month trial of fibrate therapy in the last 6 months at up to maximally indicated doses, unless contraindicated or adverse effects; 5. Failure of omega-3-acid ethyl esters (e.g., Lovaza) at up to maximally indicated doses, unless contraindicated or adverse effects; 6. Dose does not exceed 4 g per day and 4 capsules per day.TG ≥ 500 mg/dL

Approval duration 12 months

Initial Therapy - Reduction of Cardiovascular Disease Risk

Covered when ALL of the following are met

CVD risk reduction initial: 1. Diagnosis of either (a) atherosclerotic cardiovascular disease (ASCVD) evidenced by any of: acute coronary syndromes; clinically significant coronary heart disease by invasive or noninvasive testing; coronary or other arterial revascularization; myocardial infarction; peripheral arterial disease of atherosclerotic origin; stable or unstable angina; or stroke/TIA; OR (b) diabetes with ≥2 cardiovascular disease risk factors (see Appendix G); 2. Age ≥ 45 years; 3. Documentation of both labs within 90 days: fasting TG 150–499 mg/dL AND LDL‑C 41–100 mg/dL; 4. For members on statin therapy: (a) Vascepa prescribed with a statin at maximally tolerated dose; AND (b) member adherent for at least the last 8 weeks to maximally tolerated doses of one of the following statin regimens: (i) a high-intensity statin; OR (ii) a moderate or low-intensity statin when the member has either previous use of one high-intensity statin for ≥8 weeks with LDL‑C remaining ≥70 mg/dL OR has tried both rosuvastatin and atorvastatin and experienced reversible skeletal‑muscle related symptoms on both agents that resolved on discontinuation; 5. For members not on statin therapy: either (a) statin is contraindicated per Appendix F; OR (b) for statin‑intolerant members, tried at least two statins (one hydrophilic: pravastatin, fluvastatin, or rosuvastatin) and meets additional statin intolerance documentation (including SAMS criteria and rechallenge documentation); 6. Dose does not exceed 4 g per day and 4 capsules per day.TG 150-499 mg/dL; LDL-C 41-100 mg/dL

Approval duration 12 months

Continued Therapy - Hypertriglyceridemia without ASCVD

Covered when ALL of the following are met

Hypertriglyceridemia continued: 1. Member currently receiving medication via Centene benefit or has previously met initial approval criteria, or qualifies under continuity of care provisions; 2. Member is responding positively as evidenced by: (a) initial reauthorization requires ≥20% reduction in TG from baseline; (b) subsequent reauthorizations require continued reduction or maintenance of TG reduction from baseline; 3. If request is for a dose increase, new dose does not exceed 4 g per day and 4 capsules per day.20% TG reduction for initial reauth

Approval duration 12 months

Continued Therapy - Reduction of Cardiovascular Disease Risk

Covered when ALL of the following are met

CVD risk reduction continued: 1. Member currently receiving medication via Centene benefit or has previously met initial approval criteria, or qualifies under continuity of care provisions; 2. Member is responding positively as evidenced by no increase in TG and LDL‑C levels from baseline; 3. If statin tolerant, documentation of adherence to a statin at the maximally tolerated dose; 4. If request is for a dose increase, new dose does not exceed 4 g per day and 4 capsules per day.

Approval duration 12 months

Authorization and statin trial criteria

Coverage and authorization updated; specific clinical criteria for statin trial/failure and approval duration applied

Initial approval duration: Initial approval for this maintenance medication is extended to 12 months for all indications.12 months

applies to all indications

Statin trial/adherence for reduction of CVD risk: Either documented insufficient therapeutic response to one high‑intensity statin after 8 weeks OR reversible muscle‑related symptoms associated with both rosuvastatin and atorvastatin (symptoms resolved on discontinuation) as evidence of statin intolerance/trial failure.8 weeks where applicable

Simplified criteria replace prior longer-duration adherence requirements for certain moderate/low intensity regimens.

Requests for use of icosapent ethyl (Vascepa) for non‑FDA approved indications that are not specifically addressed by this policy will not be authorized unless the provider submits sufficient clinical evidence of efficacy and safety consistent with the off‑label use policy CP.CPA.09 (commercial) or applicable evidence‑of‑coverage documentation.

Contraindications relevant to statin therapy and considerations for icosapent ethyl include decompensated liver disease (signs such as jaundice, ascites, variceal bleeding, encephalopathy), laboratory‑confirmed acute liver injury or rhabdomyolysis resulting from statin treatment, pregnancy/actively trying to conceive/nursing (historical contraindication noted with FDA communications), and immune‑mediated hypersensitivity to the statin drug class demonstrated by an allergic reaction to at least two different statins.

Recent administrative updates reflect that there have been no significant clinical changes across several consecutive annual reviews. Language that previously redirected requests between generic and brand product options was removed as an administrative clarification; substantive policy changes in the 1Q 2026 review are limited to operational updates (for example, extension of initial approval duration and revisions to statin adherence/trial criteria) rather than changes to core clinical thresholds.

Key Clinical Thresholds and Coding-relevant Values

Fasting triglycerides — thresholds

Fasting triglycerides — hypertriglyceridemia thresholdFasting TG ≥ 500 mg/dL (lab within 90 days)

Fasting triglycerides — CVD risk reduction rangeFasting TG 150–499 mg/dL (labs within 90 days)

Maximum daily doseDoes not exceed 4 g per day and 4 capsules per day

LDL-C

LDL-C requirementLDL-C between 41–100 mg/dL (lab within 90 days)

Context for LDL-CRequired as part of documentation for CVD risk reduction indication

Prior Authorization, Documentation, and Step Therapy Requirements

Prior Authorization

Prior Authorization Required

Prior authorization is required. Requests must include documentation of the diagnosis and supporting clinical information. Labs (fasting triglycerides and, when requesting for CVD risk reduction, LDL-C) must be dated within 90 days of the request. Provider must also document the therapeutic trials, statin trial/adherence or statin intolerance pathway (see below), and any other clinical rationale supporting the request. Approval duration for initial requests is 12 months.

Fasting TG and, for CVD risk reduction requests, LDL-C dated within 90 days
Documentation of diagnosis and pertinent office chart notes or lab results
Initial approval duration: 12 months

Prior Authorization

Prior Authorization Criteria Updated

Prior authorization criteria were updated to: extend the initial approval duration to 12 months for this maintenance medication used for a chronic condition; for reduction of CVD risk, reduce required statin adherence duration from 4 months to 8 weeks; and simplify statin trial/failure criteria for moderate- and low-intensity statins to permit demonstration of insufficient therapeutic response to one high-intensity statin for 8 weeks or documented reversible muscle-related symptoms with both rosuvastatin and atorvastatin. Requests may be denied if revised statin trial/adherence or statin intolerance criteria are not met or if documentation is insufficient.

Background and Drug Information

Icosapent ethyl (Vascepa) is an ethyl ester of eicosapentaenoic acid (EPA) indicated as an adjunct to statin therapy to reduce cardiovascular events in adults with elevated triglycerides and for reduction of triglyceride levels in severe hypertriglyceridemia. The policy aligns coverage with FDA‑labeled indications, specifies required laboratory thresholds and prior therapy trials where applicable, and sets dosing and approval durations consistent with those indications.

Definitions and Key Terms

Icosapent ethyl (Vascepa)

DefinitionIcosapent ethyl (Vascepa) is an ethyl ester of eicosapentaenoic acid (EPA)

Indication contextUsed adjunctively with statins to reduce cardiovascular events in adults with elevated triglycerides and to reduce triglyceride levels in severe hypertriglyceridemia

Statin intensity

High-intensity statin — definition & examplesDaily dose lowering LDL‑C ≈ ≥50%. Examples: Atorvastatin 40–80 mg; Rosuvastatin 20–40 mg

Moderate-intensity statin — definition & examplesDaily dose lowering LDL‑C ≈ 30–50%. Examples: Atorvastatin 10–20 mg; Rosuvastatin 5–10 mg; Simvastatin 20–40 mg

Low-intensity statin — definition & examplesDaily dose lowering LDL‑C <30%. Examples: Simvastatin 10 mg; Pravastatin 10–20 mg; Lovastatin 20 mg

Policy Summary

Payermhn

PolicyClinical Policy: Icosapent Ethyl (Vascepa)

Policy CodePolicy CP.CPA.357

Change TypeRevised approval duration and statin trial criteria

Effective Date03.01.23

Next Review Date

Key ActionSubmit prior authorization with diagnosis, labs (fasting TG and LDL‑C) within 90 days and documentation of prior statin therapy or statin intolerance per criteria.

SourceLink

On This Page

Hypertension threshold

Hypertension thresholdSystolic ≥ 140 mmHg OR diastolic ≥ 90 mmHg (or on antihypertensive medication)

Use caseIncluded as a CVD risk factor in Appendix G

HDL-C thresholds

HDL-C threshold — menHDL‑C ≤ 40 mg/dL

HDL-C threshold — womenHDL‑C ≤ 50 mg/dL

RoleListed as a CVD risk factor in Appendix G

Renal dysfunction — creatinine clearance

Renal dysfunction (CrCL)> 30 and < 60 mL/min

ContextListed as a CVD risk factor in Appendix G

Microalbuminuria thresholds

Microalbuminuria — ACR or timed collectionAlbumin/creatinine ratio ≥ 2.5 mg/mmol OR albumin excretion rate ≥ 20 mg/min on at least two successive occasions

Alternative evidencePositive micral or other strip test may be used (documented in medical records)

Macroalbuminuria thresholds

Macroalbuminuria — ACR or timed collectionAlbumin/creatinine ratio ≥ 25 mg/mmol OR albumin excretion rate ≥ 200 mg/min on at least two successive occasions

Alternative evidenceAlbustix or other dipstick evidence of gross proteinuria

Initial approval duration extended to 12 months
For CVD risk reduction: statin adherence requirement reduced to 8 weeks
Simplified statin trial/failure pathway for moderate/low intensity regimens

Denial Risk

Non‑FDA Indications

Requests for non-FDA approved (off-label) indications that are not specifically addressed in this policy will be considered only with sufficient supporting evidence of efficacy and safety per the payer's off-label use policy (CP.CPA.09) or applicable evidence-of-coverage documents. Absent sufficient documentation, coverage is not authorized.

Non-FDA indications require evidence per CP.CPA.09 or evidence-of-coverage documents
Coverage not authorized for off-label uses without sufficient documentation

Documentation Required

Statin Trial / Adherence Documentation

Document the statin trial and adherence or documented statin intolerance clearly. For statin trials, include the statin agent(s), dose, start and stop dates, duration, and reason for discontinuation or insufficient response. For adherence, provide chart notes or pharmacy fill history showing the required trial period (e.g., 8 weeks for CVD risk reduction when applicable). Requests lacking adequate statin trial/adherence or statin intolerance documentation may be denied.

Provide statin agent, dose, start/stop dates, duration, and outcome
Adherence evidence may include pharmacy fills, medication lists, or chart notes
Insufficient documentation of statin trial/adherence or intolerance is grounds for denial

Documentation Required

Required Clinical Documentation

Required clinical documentation must include office chart notes, laboratory results (fasting TG and, when applicable, LDL-C), and any other clinical information that supports the member has met all applicable approval criteria. For hypertriglyceridemia without ASCVD, documentation must show fasting TG ≥ 500 mg/dL dated within 90 days and evidence of therapeutic trials (fibrate and omega-3-acid ethyl esters) at maximally indicated doses for the required durations unless contraindicated or not tolerated.

Office chart notes and lab results supporting diagnosis and lab thresholds
Fasting TG ≥ 500 mg/dL within 90 days for hypertriglyceridemia without ASCVD
Evidence of ≥3 months fibrate trial and trial of omega-3-acid ethyl esters at maximally indicated doses unless contraindicated

Step Therapy

Statin Trial and Intolerance Pathway

Statin trial and intolerance pathway expectations: For reduction of CVD risk, providers should document either (a) an insufficient therapeutic response after at least one high‑intensity statin for 8 weeks, or (b) reversible muscle‑related symptoms (SAMS) associated with both rosuvastatin and atorvastatin or laboratory‑confirmed statin‑related liver injury or rhabdomyolysis. For patients with true statin intolerance, provide documentation of symptoms, timelines, and any rechallenge attempts. Alternative pathways or exceptions may apply when statins are contraindicated or not tolerated; these must be clearly documented.

Insufficient response to one high‑intensity statin for ≥ 8 weeks qualifies for pathway
Reversible SAMS documented with both rosuvastatin and atorvastatin qualifies as intolerance
Laboratory-confirmed liver injury or rhabdomyolysis from statins must be documented
Document rechallenge attempts and resolution of symptoms when applicable

SAMS (Statin-associated muscle symptoms)

SAMS — typical clinical featuresMuscle pain, aching (myalgia), cramps, and weakness, usually bilateral and involving large muscle groups

Diagnosis supportOften clinical; symptom resolution with statin cessation and recurrence on rechallenge supports diagnosis

TimingSymptoms often appear early after starting or after dose increase and usually resolve within weeks after cessation

Statin contraindications

Statin contraindications — liver injury/rhabdomyolysisLaboratory-confirmed acute liver injury or rhabdomyolysis resulting from statin treatment

Statin contraindications — decompensated liver diseaseDecompensated liver disease (jaundice, ascites, variceal bleeding, encephalopathy)

Statin contraindications — immune hypersensitivityImmune-mediated hypersensitivity to statins evidenced by allergic reaction to at least two different statins